Clinical trials: Insulin Dependent Diabetes
Treatment of Type I Diabetes Mellitus.
Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy
Phase IB will evaluate the safety of autologous, ex vivo-engineered, co-stimulation impaired dendtritic cells to maintain and improve functional residual beta cell mass in new onset Type I Diabetes Mellitus (T1DM) patients.
- Trial name
- NCT01947569
- Testing
- Biological
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- DiaVacs, Inc.
Type1diabetes
Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children
To investigate in a prospective way changes in Mucosal-Associated Invariant T (MAIT) cells frequency, phenotype and function in link with the gut microbiota, gut integrity and the presence of Coxsackie virus B in two cohorts of…
- Trial name
- MAIT-DT1 (NCT05054361)
- Testing
- MAIT cells analysis, MAIT cytokines production analysis, Lactulose/Mannitol Test
- Where
- 2 sites in France
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Type 1 Diabetes Mellitus
A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes
This study consists of 2 sub-studies, including Part A and Part B. Part A is intended to further characterize the pharmacokinetic (PK) profile of PS1 based on existing single ascending dose (SAD) and multiple ascending dose (MAD)…
- Trial name
- NCT07889505
- Testing
- PS1
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Pharmasaga Co. Ltd.
Type 1 Diabetes
Ecological Momentary Assessment Study of Adolescents and Young Adults With Type 1 Diabetes (EMA-T1D)
This single site investigator-initiated prospective observational study will enroll up to 150 participants 13-26 years of age with Type 1 diabetes (T1D) and utilize ecological momentary assessment methods (EMA) to examine…
- Trial name
- NCT06129994
- Testing
- Observational
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Michigan
Diabetes, Type 1
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
The objective of this study is to demonstrate that TI® Inhalation Powder combined with Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.
- Trial name
- NCT00700622
- Testing
- Technosphere Insulin, Insulin glargine, Insulin lispro
- Where
- 22 sites in United States, Brazil
- Volunteers
- 130 people
- Sponsor
- Mannkind Corporation
Islet Transplantation, Diabetes Type 1
Imaging of Islet Transplantation With PET and MRT
Islets of Langerhans intended for clinical transplantation are labelled with a radioactive tracer. The tracer is retained in viable cells of the transplant.
- Trial name
- NCT00417131
- Where
- 2 sites in Sweden
- Volunteers
- 8 people
- Sponsor
- Uppsala University Hospital
Type1diabetes
Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes
The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS). Participants will be asked to: 1.
- Trial name
- NCT06273124
- Testing
- SteadiSet Extended Wear Infusion Set
- Where
- 15 sites in United States
- Volunteers
- 260 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 1 Diabetes Mellitus
MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes
The study is a randomized, double-masked, placebo-controlled, Phase 1 dose-escalation clinical trial. The objective of the trial is to determine if IBC adjuvanted with MAS-1 is safe and will favor tolerogenic pathways to restore…
- Trial name
- MER3101 (NCT03624062)
- Testing
- MAS-1 adjuvanted Insulin B-chain
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Colorado, Denver
Type 1 Diabetes, Diabetes Complications
Individualised Postprandial Glucose Responses in Type 1 Diabetes
Type 1 diabetes (T1D) is a lifelong disease which stops the body from producing insulin - an important hormone that controls blood sugar (glucose) levels.
- Conditions
- Type 1 Diabetes, Diabetes Complications, Postprandial Hyperglycemia
- Trial name
- NCT05231642
- Testing
- Nutritional Interventional
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- University of Sunderland
Diabetes Mellitus, Type 1
Pre Transplant Rapamycin Treatment in Islet Transplantation Alone
Numerous changes to the original Edmonton protocol have been proposed in the attempt of improving the still unsatisfactory long-term function of ITA.
- Trial name
- ITA-Rp (NCT01060605)
- Testing
- rapamycin
- Where
- Italy
- Volunteers
- 11 people
- Sponsor
- IRCCS San Raffaele
Type 1 Diabetes Mellitus
Reducing Risks and Improving Glucose Control During Extended Exercise in Youth With T1DM: The AP Ski Camp
The biggest challenges for glycemic control during the day time involve meals and exercise variations, which are impacted by age, fitness level, duration, intensity and history of exercise.
- Trial name
- NCT02604524
- Testing
- Closed-Loop Control, Sensor Augmented Pump Therapy
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Daniel Chernavvsky, MD, CRC
Diabetes
Three-day, In-clinic Evaluation of the BD 2nd Generation Continuous Glucose Sensor Device in Type 1 Diabetics
The purpose of this study is to investigate the accuracy and performance of a new subcutaneous continuous glucose monitor (BD-CGM, Becton Dickinson) in hyperglycemic (high blood sugar) and hypoglycemic (low blood sugar) "clamp"…
- Trial name
- NCT01645696
- Testing
- BD CGM with Outer Layer, BD CGM without Outer Layer, Medtronic iPro2 Professional CGM
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Becton, Dickinson and Company
Diabetes Mellitus, Type 1
Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy
This is a pilot outpatient study conducted at Stanford to obtain preliminary data on how Fiasp® works in a closed-loop system and to determine if any changes need to be made to the 670G pump to optimize the use of Fiasp®.
- Trial name
- NCT03554486
- Testing
- Fiasp, Novolog
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Stanford University
Type 1 Diabetes
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
The study is a two centre, open-label, uncontrolled single group phase 1A study of C19-A3 GNP peptide (10 μg peptide equivalent content) administered via Nanopass microneedles every 28 days for 8 weeks (3 doses), with follow-up…
- Trial name
- EE-ASI-1 (NCT02837094)
- Testing
- C19-A3 GNP
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Cardiff University
Type 1 Diabetes
Glycemic Outcomes and Safety With Minimed 780G System in Children With Type 1 Diabetes Aged 2-6 Years
The purpose of this study is to evaluate the effectiveness of advanced hybrid-closed loop system, Minimed 780G to glycemic control and safety in children aged 2-6 years with type 1 diabetes.
- Trial name
- NCT04949022
- Testing
- Medronic 780G insulin pump
- Where
- Finland
- Volunteers
- 38 people
- Sponsor
- Helsinki University Central Hospital
Type 1 Diabetes Mellitus
Artificial Pancreas Control System in an Outpatient Setting
The objectives of this outpatient research study are (1) to assess the ability of this automated system to be operated by a subject with limited professional oversight; (2) to assess whether the new devices (Dexcom Gen 4 sensors…
- Trial name
- NCT01871870
- Testing
- Artificial Pancreas Control Software
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Legacy Health System
Diabetes, Diabetes Mellitus, Type 1
Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes
The trial is conducted in Europe and Middle East. The aim of the trial is to compare the use of Insulin Detemir once or twice daily combined with mealtime Insulin Aspart against that of NPH Insulin once or twice daily combined…
- Trial name
- NCT00312156
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- 42 sites in Belgium, Croatia and 14 more
- Volunteers
- 347 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a…
- Trial name
- POLARIS (NCT06919354)
- Testing
- GNTI-122
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- GentiBio, Inc
Diabetes Mellitus, Bariatric Surgery Candidate
Paraoxonase and HDL Qualities in Glycaemia and Inflammation
The incidence of coronary heart disease (CHD) is significant in the super-obese and diabetics. Inflammation is believed to play an important part in the development of CHD, and the large collection of abdominal fat in the obese…
- Trial name
- PON1 (NCT02169518)
- Where
- United Kingdom
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Manchester University NHS Foundation Trust
Hypertension
Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy
To evaluate the impact of spironolactone treatment on renal autoregulation in hypertensive type 1 diabetic patients.
- Trial name
- NCT00335413
- Testing
- Spironolactone
- Volunteers
- 17 people
- Sponsor
- Steno Diabetes Center Copenhagen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.